This one is ready, hit $100 on solid news, dropped after funding round, now ready to start a march back up towards the $90's...
Solid move on really good data, this company has a bright future, now to see if they do an offering.
This is a signal that KRYS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked back and found 25 similar cases where KRYS's RSI Indicator left the overbought zone, and in 20 of them led to a successful outcome. Odds of Success: 80%. Current price $64.14 is above...
These are my thoughts on KRYS. They are meant to give you an idea, not trading advice. This chart comes together like lego. Just don't step on it. Target around 80$. Could take a few months. Dips below 40$ are my buying opportunities. Not saying it can't go lower. Please be careful, as the market never gives you certainties, only probabilities! ALWAYS...
KRYS: Krystal Biotech, Inc. 2020-05-14 08:00:10 Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI)
KRYS has hit FIB golden ratio resistance and peaked out on 5th wave. Looking for pullback to low $40's then we'll find out if it wants to fill the gap. Please like/ comment so I can continue looking for awesome trades. Thank you in advance. Message me if your interested in learning more on pattern analysis . Follow trend, Buy low sell high!! Follow me on...
KRYS broke its mid and long term resistance yesterday with high volume. There is a probability the price would test its' new support at $39 area before continuing its' move upward.
KRYS: Krystal Biotech, Inc. 2019-06-24 08:00:00 Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103 - GlobeNewswire
KRYS: Krystal Biotech, Inc. 2018-08-23 08:00:00 Krystal Biotechs’ KB105 Receives Rare Pediatric Disease Designation from the FDA to Treat Patients with TGM-1-deficient Autosomal Recessive Congenital Ichthyosis
KRYS: Krystal Biotech 2018-08-09 08:00:00 Krystal Biotech’s KB105 Granted Orphan Drug Designation by the FDA to Treat Patients With TGM-1 Deficient Autosomal Recessive Congenital Ichthyosis